We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.19%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$522M
AUM Growth
-$148M
Cap. Flow
-$183M
Cap. Flow %
-35.1%
Top 10 Hldgs %
68.85%
Holding
172
New
42
Increased
30
Reduced
27
Closed
64

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.7M
2
AZN icon
AstraZeneca
AZN
+$11.5M
3
XWEL icon
XWELL
XWEL
+$3.81M
4
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$3.63M
5
CVM icon
CEL-SCI Corp
CVM
+$2.66M

Top Sells

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$4.87M
2
IMMU
Immunomedics Inc
IMMU
+$4.25M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.12M
4
SPI
SPI Energy Co., Ltd. Ordinary Shares
SPI
+$3.57M
5
RMTI icon
Rockwell Medical
RMTI
+$3.04M

Sector Composition

Rank Sector Weight
1 Healthcare 17.64%
2 Industrials 0.71%
3 Technology 0.22%
4 Consumer Discretionary 0.14%
5 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLRB icon
51
Cellectar Biosciences
CLRB
$19.8M
$1.04M 0.2%
+1,663
New +$764K
ATNM icon
52
CALL
Actinium Pharmaceuticals
ATNM
$26.3M
$1.02M 0.2%
+1,308
New +$14.2K
ODT
53
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$921K 0.18%
47,945
-30,333
-39% -$468K
AUPH icon
54
Aurinia Pharmaceuticals
AUPH
$1.95B
$774K 0.15%
55,943
+42,399
+313% +$617K
MTVA
55
MetaVia Inc
MTVA
$7.44M
$748K 0.14%
54
-15
-22% -$226K
KNDI
56
Kandi Technologies Group
KNDI
$66.5M
$729K 0.14%
+105,714
New +$870K
CRMD icon
57
PUT
CorMedix
CRMD
$564M
$664K 0.13%
894
+785
+720% +$5.34K
MRTX
58
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$659K 0.13%
+3,000
New +$649K
CBAT icon
59
PUT
CBAK Energy Technology Ltd
CBAT
$43.1M
$629K 0.12%
+2,938
New +$14.3K
NBRV
60
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$629K 0.12%
10,400
+9,328
+870% +$1.01M
CRMD icon
61
CALL
CorMedix
CRMD
$564M
$623K 0.12%
839
+603
+256% +$4.1K
RMTI icon
62
Rockwell Medical
RMTI
$27.2M
$618K 0.12%
5,564
-27,122
-83% -$3.04M
BLCM
63
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$563K 0.11%
+159,500
New +$673K
CTRM icon
64
Castor Maritime
CTRM
$18.3M
$527K 0.1%
+28,506
New +$444K
XWEL icon
65
PUT
XWELL
XWEL
$8.95M
$506K 0.1%
213
+87
+69% +$3.07K
BHVN
66
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$454K 0.09%
+53
New +$4.49K
FEED
67
ENvue Medical Inc
FEED
$2.01M
$446K 0.09%
+265
New +$433K
ORMP icon
68
PUT
Oramed Pharmaceuticals
ORMP
$162M
$420K 0.08%
+991
New +$3.23K
AVEO
69
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$393K 0.08%
68,092
+42,053
+162% +$241K
ALNA
70
DELISTED
Allena Pharmaceuticals
ALNA
$345K 0.07%
+269,836
New +$376K
AMBO
71
Ambow Education Holding
AMBO
$6.24M
$329K 0.06%
+15,177
New +$404K
ITCI
72
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$318K 0.06%
+100
New +$2.63K
LIXTW
73
DELISTED
Lixte Biotechnology Warrants
LIXTW
$306K 0.06%
+339,542
New +$306K
ATNM icon
74
PUT
Actinium Pharmaceuticals
ATNM
$26.3M
$297K 0.06%
381
+217
+132% +$2.36K
EVOK
75
PUT
DELISTED
Evoke Pharma
EVOK
$289K 0.06%
8
-3
-27% -$1.55K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sabby Management held 172 positions worth $522M, down 22% from $670M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $183M in Q4 2020, closing 64 positions and reducing 27 holdings. Its most notable exit was Sorrento Therapeutics, Inc., an estimated $4.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 12% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sabby Management opened a new position in REVIVA PHARMA HLDGS INC worth $3.13M.

  • Sabby Management's largest Q4 2020 buy was REVIVA PHARMA HLDGS INC: 17,915 shares worth $3.13M.
  • Sabby Management added most to Biogen in Q4 2020, an estimated $18.7M increase.
  • Sabby Management's biggest Q4 2020 reduction was Rockwell Medical, cutting an estimated $3.04M.
  • Sabby Management fully exited Sorrento Therapeutics, Inc. in Q4 2020, selling an estimated $4.87M.
  • Sabby Management's ten largest holdings make up 69% of its $522M portfolio in Q4 2020.
  • Sabby Management opened 42 new positions and closed 64 in Q4 2020.
  • Sabby Management's portfolio value fell 22% quarter-over-quarter to $522M.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.